Ovarian Cancer Therapy by VSVMP Gene Mediated by a Paclitaxel-Enhanced Nanoparticle

• DOI: 10.1021/acsami.7b10796
• Publication Date: 2017-09-25T09:34:11Z
• Authors: Jianlin Long; Yuping Yang; Tianyi Kang; Wei Zhao; Hao Cheng; Yujiao Wu; Ting Du; Beibei Liu; Yang Li; Feng Luo; Maling Gou
• Keywords: Ovarian Neoplasms; 0301 basic medicine; Viral Proteins; 03 medical and health sciences; Paclitaxel; Cell Line, Tumor; Humans; Nanoparticles; Apoptosis; Female; 3. Good health

Nanoparticles have great promise for gene delivery. However, the transfection efficiency of nanoparticle-based delivery systems is always unsatisfied to meet requirement effective therapy. Herein, we used low-dosage paclitaxel enhance a nanoscaled system that was self-assembled from N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammoniummethyl sulfate and monomethoxy poly(ethylene glycol)-poly(d,l-lactide) (DPP), creating paclitaxel-encapsulated DPP (P-DPP) nanoparticle. The encapsulated significantly improved nanoparticles against multiple cancer cells, in some which as high 92%. By P-DPP nanoparticle, vesicular stomatitis virus matrix protein (VSVMP) could induce cell apoptosis delivered treat ovarian cancer. encapsulation increased expression VSVMP, enhancing VSVMP antiproliferation SKOV3 cells. Intraperitoneal administration P-DPP-delivered effectively inhibited intraperitoneal metastasis cancer, more efficient than DPP-delivered VSVMP. Moreover, it found tumor induction, proliferation inhibition, angiogenesis suppression were involved anticancer mechanism this nanocomplex. Our data suggest can cells exert synergistic effect with treatment. therapy by paclitaxel-enhanced nanoparticle has potential application